Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China - Business Wire businesswire.com Submitted by businesswire3560 on June 1, 2024 at 12:08 PM in business No comments 42